Exhibit 99.1
EUCRATES BIOMEDICAL ACQUISITION CORPORATION
BALANCE SHEET
OCTOBER 27, 2020
October 27, 2020 | Pro Forma Adjustments | As Adjusted | ||||||||||
(unaudited) | (unaudited) | |||||||||||
ASSETS | ||||||||||||
Current assets | ||||||||||||
Cash | $ | 711,200 | $ | — | $ | 711,200 | ||||||
Prepaid expenses and other current assets | 520,400 | — | 520,400 | |||||||||
Total Current Assets | 1,231,600 | — | 1,231,600 | |||||||||
Cash held in Trust Account | 100,000,000 | 4,796,260 | 104,796,260 | |||||||||
Total Assets | $ | 101,231,600 | $ | 4,796,260 | $ | 106,027,860 | ||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||
Current Liabilities | ||||||||||||
Accrued expenses | $ | 2,140 | $ | — | $ | 2,140 | ||||||
Accrued offering costs | 114,610 | — | 114,610 | |||||||||
Total Current Liabilities | 116,714 | — | 116,714 | |||||||||
Deferred underwriting fee payable | 3,500,000 | 167,869 | 3,667,869 | |||||||||
Total Liabilities | 3,616,714 | 167,869 | 3,784,583 | |||||||||
Commitments and Contingencies | ||||||||||||
Ordinary shares subject to possible redemption, 9,261,488 and 9,724,327 shares at redemption value, respectively | 92,614,880 | 4,628,390 | 97,243,270 | |||||||||
Stockholders’ Equity | ||||||||||||
Ordinary shares, no par value; unlimited shares authorized; 3,963,512 and 3,734,798 shares issued and outstanding (excluding 9,261,488 and 9,724,327 shares subject to possible redemption), respectively | 5,004,938 | 1 | 5,004,939 | |||||||||
Accumulated deficit | (4,932 | ) | — | (4,932 | ) | |||||||
Total Shareholders’ Equity | 5,000,006 | 1 | 5,000,007 | |||||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 101,231,600 | $ | 4,796,260 | $ | 106,027,860 |